Spots Global Cancer Trial Database for mesothelioma, malignant
Every month we try and update this database with for mesothelioma, malignant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours | NCT05698238 | Clear Cell Rena... TNBC - Triple-N... Head and Neck C... Non-small-cell ... Mesothelioma, M... | CA9hu-1 | 18 Years - 80 Years | Mabpro, a.s. | |
| ......SMARTEST Trial...... | NCT05380713 | Mesothelioma, M... | Cyclophosphamid... Tremelimumab Durvalumab | 18 Years - 95 Years | University Health Network, Toronto | |
| A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants | NCT05136677 | Mesothelioma, M... | Nivolumab Ipilimumab Pemetrexed Cisplatin Carboplatin | 18 Years - | Bristol-Myers Squibb | |
| First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma | NCT05188859 | Mesothelioma, M... Mesothelioma, M... Mesothelioma Ma... | Sintilimab+Anlo... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | NCT05568680 | Ovarian Cancer Cholangiocarcin... Mesothelioma, M... | SynKIR-110, Aut... | 18 Years - | Verismo Therapeutics | |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | NCT05451849 | Mesothelioma Mesotheliomas P... Mesothelioma, M... Mesothelioma Pe... Ovarian Cancer Ovarian Serous ... Pancreatic Canc... Pancreatic Aden... Colorectal Canc... Triple Negative... TNBC - Triple-N... Ovarian Adenoca... Pancreatic Neop... Colorectal Neop... Ovarian Neoplas... Cholangiocarcin... Non Small Cell ... | TC-510 Fludarabine Cyclophosphamid... | 18 Years - | TCR2 Therapeutics | |
| Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours | NCT05698238 | Clear Cell Rena... TNBC - Triple-N... Head and Neck C... Non-small-cell ... Mesothelioma, M... | CA9hu-1 | 18 Years - 80 Years | Mabpro, a.s. | |
| A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | NCT04104776 | Advanced Solid ... Diffuse Large B... Lymphoma, T-Cel... Mesothelioma, M... Prostatic Neopl... Endometrial Can... Ovarian Clear C... | CPI-0209 | 18 Years - | Constellation Pharmaceuticals | |
| SW-682 in Advanced Solid Tumors | NCT06251310 | Advanced Solid ... Mesothelioma, M... | SW-682 Combination The... | 18 Years - | SpringWorks Therapeutics, Inc. | |
| Malignant Mesothelioma - Can we Improve Quality of Life | NCT03068117 | Mesothelioma, M... | Regular Early S... | 18 Years - | Portsmouth Hospitals NHS Trust | |
| Niraparib Efficacy in Patient With Unresectable Mesothelioma | NCT05455424 | Mesothelioma, M... | Niraparib Oral ... Active Symptom ... | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) | NCT02357147 | Mesothelioma, M... | Placebo Amatuximab Pemetrexed Cisplatin | 18 Years - | Morphotek | |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | NCT03907852 | Mesothelioma Mesothelioma, M... Mesothelioma; P... Mesotheliomas P... Mesothelioma Pe... Cholangiocarcin... Cholangiocarcin... Ovarian Cancer Non Small Cell ... Non Small Cell ... High Grade Ovar... | gavo-cel fludarabine cyclophosphamid... Nivolumab Ipilimumab | 18 Years - | TCR2 Therapeutics | |
| ......SMARTEST Trial...... | NCT05380713 | Mesothelioma, M... | Cyclophosphamid... Tremelimumab Durvalumab | 18 Years - 95 Years | University Health Network, Toronto | |
| Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours | NCT05698238 | Clear Cell Rena... TNBC - Triple-N... Head and Neck C... Non-small-cell ... Mesothelioma, M... | CA9hu-1 | 18 Years - 80 Years | Mabpro, a.s. | |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | NCT05451849 | Mesothelioma Mesotheliomas P... Mesothelioma, M... Mesothelioma Pe... Ovarian Cancer Ovarian Serous ... Pancreatic Canc... Pancreatic Aden... Colorectal Canc... Triple Negative... TNBC - Triple-N... Ovarian Adenoca... Pancreatic Neop... Colorectal Neop... Ovarian Neoplas... Cholangiocarcin... Non Small Cell ... | TC-510 Fludarabine Cyclophosphamid... | 18 Years - | TCR2 Therapeutics | |
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies | NCT03546426 | Mesothelioma, M... PD-L1 Negative Advanced Cancer Progressive Dis... | Pembrolizumab Autologous dend... Interleukin-2 | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) | NCT02519049 | Mesothelioma, M... | No intervention | 18 Years - | Istituto Clinico Humanitas | |
| Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration | NCT06281860 | Mesothelioma, M... Carcinoma, Non-... Carcinoma Breas... Ovarian Cancer Esophageal Canc... Gastric Cancer | Cisplatine Teva... | 18 Years - | Centre Hospitalier Universitaire Vaudois | |
| Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma | NCT04823741 | Mesothelioma, M... Gene Abnormalit... Pleural Mesothe... | PLEURAL BIOCOLL... | 18 Years - 95 Years | Hospices Civils de Lyon | |
| Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma | NCT04823741 | Mesothelioma, M... Gene Abnormalit... Pleural Mesothe... | PLEURAL BIOCOLL... | 18 Years - 95 Years | Hospices Civils de Lyon | |
| Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma | NCT03393858 | Cancer Mesothelioma, M... | Anti-PD-1 antib... DC-CIK Immunoth... Thermotron RF-8... | 18 Years - 80 Years | Capital Medical University | |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | NCT04981119 | Solid Tumor, Ad... Colorectal Canc... Non Small Cell ... Pancreatic Canc... CRC NSCLC Pancreas Cancer Mesothelioma Ovarian Cancer Ovarian Neoplas... Ovarian Carcino... Mesothelioma, M... Mesothelioma; L... Cancer | Apheresis Next Generation... Long Range NGS ... | 18 Years - | A2 Biotherapeutics Inc. | |
| Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma | NCT03393858 | Cancer Mesothelioma, M... | Anti-PD-1 antib... DC-CIK Immunoth... Thermotron RF-8... | 18 Years - 80 Years | Capital Medical University | |
| Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma | NCT02303899 | Mesothelioma, M... | Gemcitabine Imatinib mesyla... | 18 Years - | Istituto Clinico Humanitas | |
| Isolated Thoracic Perfusion (ITP-F) for MPM | NCT02467426 | Mesothelioma | Chemotherapy | 18 Years - 80 Years | Medias Klinikum for Surgical Oncology | |
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies | NCT03546426 | Mesothelioma, M... PD-L1 Negative Advanced Cancer Progressive Dis... | Pembrolizumab Autologous dend... Interleukin-2 | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Niraparib Efficacy in Patient With Unresectable Mesothelioma | NCT05455424 | Mesothelioma, M... | Niraparib Oral ... Active Symptom ... | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Niraparib Efficacy in Patient With Unresectable Mesothelioma | NCT05455424 | Mesothelioma, M... | Niraparib Oral ... Active Symptom ... | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Immunological Variables Associated to ICI Toxicity in Cancer Patients | NCT05429866 | Breast Cancer Melanoma Non Small Cell ... Non-melanoma Sk... Gastrointestina... Head and Neck C... Renal Cell Carc... Small Cell Lung... Mesothelioma, M... Bladder Cancer Merkel Cell Car... Hepatocellular ... MSI-H Colorecta... | Checkpoint Bloc... | 18 Years - | Jules Bordet Institute | |
| SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | NCT05568680 | Ovarian Cancer Cholangiocarcin... Mesothelioma, M... | SynKIR-110, Aut... | 18 Years - | Verismo Therapeutics | |
| 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) | NCT02519049 | Mesothelioma, M... | No intervention | 18 Years - | Istituto Clinico Humanitas |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
